Abstract
The pathophysiological processes underlying bronchiectasis in chronic obstructive pulmonary disease (COPD) are not understood. In COPD, both small and large airways are progressively lost. It is currently not known to what extent the different airway generations of patients with COPD and bronchiectasis are involved.
COPD explant lungs with bronchiectasis were compared to COPD explant lungs without bronchiectasis and unused donor lungs as controls. In order to investigate all airway generations, a multimodal imaging approach using different resolutions was conducted. Per group, five lungs were frozen (n=15) and underwent computed tomography (CT) imaging for large airway evaluation, with four tissue cores per lung imaged for measurements of the terminal bronchioles. Two additional lungs per group (n=6) were air-dried for lobar microCT images that allow airway segmentation and three-dimensional quantification of the complete airway tree.
COPD lungs with bronchiectasis had significantly more airways compared to COPD lungs without bronchiectasis (p<0.001), with large airway numbers similar to control lungs. This difference was present in both upper and lower lobes. Lack of tapering was present (p=0.010) and larger diameters were demonstrated in lower lobes with bronchiectasis (p=0.010). MicroCT analysis of tissue cores showed similar reductions of tissue percentage, surface density and number of terminal bronchioles in both COPD groups compared to control lungs.
Although terminal bronchioles were equally reduced in COPD lungs with and without bronchiectasis, significantly more large and small airways were found in COPD lungs with bronchiectasis.
Abstract
Although terminal bronchioles are equally reduced in COPD lungs with and without bronchiectasis, significantly more large and small airways are found in COPD lungs with bronchiectasis http://bit.ly/2YJ5kKs
Footnotes
This article has supplementary material available from erj.ersjournals.com
Support statement: This study was supported by the KU Leuven Research Fund (C24/15/030) and the AstraZeneca Chair in respiratory pathophysiology KU Leuven. The Ghent University Special Research Fund (BOF-UGent) is acknowledged for the financial support to the Centre of Expertise UGCT (BOF.EXP.2017.000007). Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: S. Everaerts reports grants from FWO, Flemish research fund (11V9417N), during the conduct of the study.
Conflict of interest: J.E. McDonough has nothing to disclose.
Conflict of interest: S.E. Verleden has nothing to disclose.
Conflict of interest: I. Josipovic has nothing to disclose.
Conflict of interest: M. Boone has nothing to disclose.
Conflict of interest: A. Dubbeldam has nothing to disclose.
Conflict of interest: C. Mathyssen has nothing to disclose.
Conflict of interest: J. Serré has nothing to disclose.
Conflict of interest: L.J. Dupont has nothing to disclose.
Conflict of interest: G. Gayan-Ramirez has nothing to disclose.
Conflict of interest: J. Verschakelen has nothing to disclose.
Conflict of interest: J.C. Hogg has nothing to disclose.
Conflict of interest: G.M. Verleden has nothing to disclose.
Conflict of interest: B.M. Vanaudenaerde has nothing to disclose.
Conflict of interest: W. Janssens reports grants from AstraZeneca, Chiesi and Boehringer Ingelheim, outside the submitted work.
- Received November 13, 2018.
- Accepted August 3, 2019.
- Copyright ©ERS 2019